Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

Cited by (1,000)

Items 201–300 of 1,000

1. Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies
   Antonio Nuccio, Giuseppe Viscardi, Fabio Salomone, Alberto Servetto, F.M. Venanzi, Silvia Teresa Riva, Sara Oresti, Francesca Rita Ogliari, Mariagrazia Viganò, Alessandra Bulotta et al. · 2023 · European Journal of Cancer
2. The Genetic Analysis and Clinical Therapy in Lung Cancer: Current Advances and Future Directions
   Angela Rina, Debora Maffeo, Francesca Minnai, Martina Esposito, Maria Palmieri, Viola Bianca Serio, Diletta Rosati, Francesca Mari, Elisa Frullanti, Francesca Colombo · 2024 · Cancers
3. Liquid Biopsy Approaches for Cancer Characterization, Residual Disease Detection, and Therapy Monitoring
   Jacqueline V. Aredo, Amna Jamali, Jessica Zhu, Natalie Knox Heater, Heather A. Wakelee, Christos Vaklavas, Valsamo Anagnostou, Janice M. Lu · 2025 · American Society of Clinical Oncology Educational Book
4. A systematic review of neoadjuvant and definitive immunotherapy in locally advanced head and neck squamous cell carcinoma
   Udit Nindra, Joshua Hurwitz, Dion F. Forstner, Venessa T. Chin, Richard M. Gallagher, Jia Liu · 2023 · Cancer Medicine
5. Neoadjuvant Versus Adjuvant Systemic Therapy for Early-Stage Non-Small Cell Lung Cancer: The Changing Landscape Due to Immunotherapy
   Ajoy Oommen John, Nithya Ramnath · 2023 · The Oncologist
6. EGFR-Targeted Therapies: A Literature Review
   Calista Sha, Paul C. Lee · 2024 · Journal of Clinical Medicine
7. Induction immune-checkpoint inhibitors for resectable oncogene-mutant NSCLC: A multicenter pooled analysis
   Chao Zhang, Huafei Chen, Yan Shi, Lin Wu, Li‐Xu Yan, Xiaolong Yan, Dongsheng Yue, C. Xu, Min Zheng, Jisheng Li et al. · 2022 · npj Precision Oncology
8. Biomarkers for Immune Checkpoint Inhibitor Response in NSCLC: Current Developments and Applicability
   Katiane Tostes, Aléxia Polo Siqueira, Rui Manuel Reis, Letícia Ferro Leal, Lídia Maria Rebolho Batista Arantes · 2023 · International Journal of Molecular Sciences
9. Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non–Small Cell Lung Cancer
   Biagio Ricciuti, Francesca Fusco, Alissa Jamie Cooper, Edoardo Garbo, Federica Pecci, Mihaela D. Aldea, Xinan Wang, María Mayoral, Michelle S. Ginsberg, Lynette Marie Sholl et al. · 2025 · JAMA Oncology
10. Predictors of survival to immunotherapy and chemoimmunotherapy in non-small cell lung cancer: A meta-analysis
    Alessandro Di Federico, Andrea De Giglio, Francesco Gelsomino, Francesca Sperandi, Barbara Melotti, Andrea Ardizzoni · 2022 · JNCI Journal of the National Cancer Institute
11. Advances and future directions in ROS1 fusion-positive lung cancer
    Boulanger, Mary C, Schneider, Jaime L, Lin, Jessica J · 2024 · The Oncologist
12. Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the College of American Pathologists, Association for Molecular Pathology, International Association for the Study of Lung Cancer, Pulmonary Pathology Society, and LUNGevity Foundation
    Sholl, Lynette M., Awad, Mark, Basu Roy, Upal, Beasley, Mary Beth, Cartun, Richard Walter, Hwang, David M., Kalemkerian, Gregory, Lopez-Rios, Fernando, Mino-Kenudson, Mari, Paintal, Ajit et al. · 2024 · Archives of Pathology & Laboratory Medicine
13. Recent Advancement of PD-L1 Detection Technologies and Clinical Applications in the Era of Precision Cancer Therapy
    Yuanfeng Zhang, Juanjuan Wu, Chaobin Zhao, Shuyuan Zhang, Jianbo Zhu · 2023 · Journal of Cancer
14. Proposed quality indicators and recommended standard reporting items in performance of EBUS bronchoscopy: An official World Association for Bronchology and Interventional Pulmonology Expert Panel consensus statement
    Daniel Steinfort, Matthew Evison, Ashleigh Witt, Georgios Tsaknis, Fayez M. Kheir, David Manners, Karan Madan, Calvin Sidhu, Alberto Fantin, Daniel Arnoldus Korevaar et al. · 2023 · Respirology
15. Immunotherapy for Head and Neck Squamous Cell Carcinoma: Current Status and Perspectives
    Amaury Daste, Mathieu Larroquette, Nyere Gibson, Matthieu Lasserre, Charlotte Domblides · 2023 · Immunotherapy
16. Challenges and controversies in resectable non-small cell lung cancer: a clinician’s perspective
    Ilias Houda, Chris Dickhoff, Carin A. Uyl‐de Groot, Ronald A.M. Damhuis, Noemí Reguart, Mariano Provencio, Antonin Lévy, Rafał Dziadziuszko, Cecilia Pompili, Massimo Di Maïo et al. · 2024 · The Lancet Regional Health - Europe
17. Stereotactic body radiotherapy with sequential tislelizumab and chemotherapy as neoadjuvant therapy in patients with resectable non-small-cell lung cancer in China (SACTION01): a single-arm, single-centre, phase 2 trial
    Ze-Rui Zhao, Shiliang Liu, Ting Zhou, Gang Chen, Hao Long, Xiaodong Su, Xu Zhang, Jianhua Fu, Peng Lin, Lanjun Zhang et al. · 2024 · The Lancet Respiratory Medicine
18. Exosomal ncRNAs in liquid biopsies for lung cancer
    Md Sadique Hussain, Gaurav Gupta, Nehmat Ghaboura, Ehssan H. O. Moglad, Waleed Hassan Almalki, Sami Ibrahim Alzarea, Imran Ahmed Kazmi, Haider Ali, Ronan J. MacLoughlin, Raimar Löebenberg et al. · 2024 · Clinica Chimica Acta
19. Network approach in liquidomics landscape
    Santini, Daniele, Botticelli, Andrea, Galvano, Antonio, Iuliani, Michele, Incorvaia, Lorena, Gristina, Valerio, Taffon, Chiara, Foderaro, Simone, Paccagnella, Elisa, Simonetti, Sonia et al. · 2023 · Journal of Experimental & Clinical Cancer Research
20. Neoadjuvant immunotherapy for advanced, resectable non–small cell lung cancer: A systematic review and meta‐analysis
    Yajing Wu, Vivek Verma, Carl Michael Gay, Yujia Chen, Fei Liang, Qiang Lin, Jianing Wang, Wei Zhang, Zhouguang Hui, Min Zhao et al. · 2023 · Cancer
21. CD47: The Next Frontier in Immune Checkpoint Blockade for Non-Small Cell Lung Cancer
    Asa P. Y. Lau, Sharon S. Khavkine Binstock, Kelsie L. Thu · 2023 · Cancers
22. Inflammation in the tumor-adjacent lung as a predictor of clinical outcome in lung adenocarcinoma
    Igor Dolgalev, Hua Zhou, Nina Murrell, Hortense Le, Theodore Sakellaropoulos, Nicolas Coudray, Kelsey Zhu, Varshini Vasudevaraja, Anna H. Yeaton, Chandra Goparaju et al. · 2023 · Nature Communications
23. Rapid Advances in Resectable Non–Small Cell Lung Cancer
    Howard West, Jae Yul Kim · 2023 · JAMA Oncology
24. The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer
    Elizabeth G. Dunne, Cameron N. Fick, James M. Isbell, Jamie E. Chaft, Nasser Khaled Altorki, Bernard J. Park, Jonathan David Spicer, Patrick M. Forde, Daniel Richard Gomez, Puneeth Iyengar et al. · 2024 · The Annals of Thoracic Surgery
25. ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies
    Darin Poei, Sana Ali, Shirley Ye, Robert C. Hsu · 2024 · Cancer Drug Resistance
26. NSCLC: Current Evidence on Its Pathogenesis, Integrated Treatment, and Future Perspectives
    Kareem Tahayneh, Mayar Idkedek, Firas Emad Abu Akar · 2025 · Journal of Clinical Medicine
27. Translating premalignant biology to accelerate non-small-cell lung cancer interception
    Sarah A. Mazzilli, Zahraa Rahal, Maral J. Rouhani, Sam M. Janes, Humam N. Kadara, Steven M. Dubinett, Avrum E. Spira · 2025 · Nature reviews. Cancer
28. Immunotherapy and senolytics in head and neck squamous cell carcinoma: phase 2 trial results
    Niu Liu, Jiaying Wu, Enze Deng, Jianglong Zhong, Bin Wei, Tingting Cai, Zhijun Xie, Xiaohui Duan, Sha Fu, David O. Osei-Hwedieh et al. · 2025 · Nature Medicine
29. What is the optimal duration of immune checkpoint inhibitors in malignant tumors?
    Jiaxin Yin, Yuxiao Song, Jiazhuo Tang, Bicheng Zhang · 2022 · Frontiers in Immunology
30. Trends in Stage I Lung Cancer
    Aashray Singareddy, Mary Ellen Flanagan, Pamela Parker Samson, Saiama Naheed Waqar, Siddhartha H. K. Devarakonda, Jeffrey P. Ward, Brett H. Herzog, Anjali Rohatgi, Clifford G. Robinson, Feng Gao et al. · 2022 · Clinical Lung Cancer
31. Enhanced anticancer activity of encapsulated geraniol into biocompatible lipid nanoparticles against A549 human lung cancer cells
    Boris Rodenak‐Kladniew, Rocío Celeste Gambaro, José Sebastián Cisneros, Cristián Huck‐Iriart, Gisel Padula, Guillermo Raul Castro, Cecilia Y. Chain, German Abel Islan · 2023 · Journal of Drug Delivery Science and Technology
32. Efficacy evaluation of neoadjuvant immunotherapy plus chemotherapy for non-small-cell lung cancer: comparison of PET/CT with postoperative pathology
    You Cheng, Zhiyong Chen, Jian-Jiang Huang, Dan Shao · 2023 · European Radiology
33. Revisiting the concept of neoadjuvant and induction therapy in head and neck cancer with the advent of immunotherapy
    Davide Smussi, Davide Mattavelli, Alberto Paderno, Cristina Gurizzan, Luigi Lorini, Chiara Romani, Eliana Bignotti, Alberto Grammatica, Marco Ravanelli, Paolo Bossi · 2023 · Cancer Treatment Reviews
34. New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across Europe
    Ilias Houda, Chris Dickhoff, Carin A. Uyl‐de Groot, Noemı́ Reguart, Mariano Provencio, Antonin Lévy, Rafał Dziadziuszko, Cecilia Pompili, Massimo Di Maïo, Michael Thomas et al. · 2024 · The Lancet Regional Health - Europe
35. Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II–III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory study
    Haoran Xia, Han Zhang, Zheng Ruan, Huibiao Zhang, Liangdong Sun, Hezhong Chen, Yongxin Zhou, Lele Zhang, Dongliang Bian, Xinsheng Zhu et al. · 2024 · Signal Transduction and Targeted Therapy
36. Less is more: Exploring neoadjuvant immunotherapy as a de-escalation strategy in head and neck squamous cell carcinoma treatment
    Lei‐Ming Cao, Nian‐Nian Zhong, Yang Chen, Zi‐Zhan Li, Guang-Rui Wang, Yao Xiao, Xuan-Hao Liu, Jun Jia, Bing Liu, Lin‐Lin Bu · 2024 · Cancer Letters
37. Lung Nodule Management in Low-Dose CT Screening for Lung Cancer: Lessons from the NELSON Trial
    Danrong Zhong, Grigory A. Sidorenkov, Colin Jacobs, Pim A. de Jong, Hester A. Gietema, Ralph Stadhouders, Kristiaan Nackaerts, Joachim G.J.V. Aerts, Mathias Prokop, Harry J.M. Groen et al. · 2024 · Radiology
38. Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response-Stratified Chemoradiation Therapy in HPV-Negative Head and Neck Cancer
    Ari Joseph Rosenberg, Aditya Juloori, Michael J. Jelinek, Nishant Agrawal, John Cursio, Nicole A. Cipriani, Mark William Lingen, Evgeny Izumchenko, Rohan Reddy Katipally, Jeffrey Chin et al. · 2025 · JAMA Oncology
39. Current challenges and practical aspects of molecular pathology for non-small cell lung cancers
    Paul M Hofman, Sabina Berezowska, Daniel N. Kazdal, Baharia Mograbi, Marius Ilié, Albrecht Stenzinger, Véronique Hofman · 2023 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
40. Expanding Horizons for Treatment of Early-Stage Lung Cancer
    Christine Marie Lovly · 2022 · New England Journal of Medicine
41. Non-small-cell lung cancer: how to manage BRAF-mutated disease
    Giorgia Guaitoli, Lodovica Zullo, Marcello Tiseo, Matthew Dankner, April A. N. Rose, Francesco Facchinetti · 2023 · Drugs in Context
42. Financial Toxicity in Patients With Resected Lung Cancer
    Nathaniel Deboever, Michael A. Eisenberg, Wayne Lewis Hofstetter, Reza John Mehran, David C. Rice, Jack A. Roth, Boris Sepesi, Stephen G. Swisher, Ara Asadur Vaporciyan, Garrett L. Walsh et al. · 2023 · Annals of Surgery
43. Lung Cancer in Indonesia
    Oke Dimas Asmara, Eric Daniel Tenda, Gurmeet Singh, Ceva Wicaksono Pitoyo, Cleopas Martin Rumende, Wulyo Rajabto, Nur Rahmi Ananda, Ika Trisnawati, Eko Budiyono, Harik Firman Thahadian et al. · 2023 · Journal of Thoracic Oncology
44. Artificial Intelligence–Powered Assessment of Pathologic Response to Neoadjuvant Atezolizumab in Patients With NSCLC: Results From the LCMC3 Study
    Sanja Đačić, William David Travis, Jennifer Margaret Giltnane, Filip Kos, John Abel, Stephanie Hilz, Junya Fujimoto, Lynette Marie Sholl, Jon M. Ritter, Farah K Khalil et al. · 2023 · Journal of Thoracic Oncology
45. A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma
    Chang Gon Kim, Min Hee Hong, Dahee Kim, Brian Hyohyoung Lee, Hyunwook Kim, Chan‐Young Ock, Geoffrey Kelly, Yoon Ji Bang, Gamin Kim, Jung Eun Lee et al. · 2024 · Clinical Cancer Research
46. Interferon-γ-stimulated antigen-presenting cancer-associated fibroblasts hinder neoadjuvant chemoimmunotherapy efficacy in lung cancer
    Zhengqi Cao, Zhouwenli Meng, Jian Li, Yu Tian, Li Lu, Anni Wang, Jia Huang, Jingze Wang, Jing Sun, Lixuan Chen et al. · 2025 · Cell Reports Medicine
47. Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systematic review and meta-analysis of randomised clinical trials
    Daniele Marinelli, Filippo Tommaso Gallina, Sergio Pannunzio, Mattia Alberto Di Civita, Andrea Torchia, Raffaele Giusti, Alain Jonathan Gelibter, Michela Roberto, Monica Verrico, Enrico Melis et al. · 2023 · Critical Reviews in Oncology/Hematology
48. [18F]FDG PET-CT radiomics signature to predict pathological complete response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer: a multicenter study
    Minglei Yang, Xiaoxiao Li, Chuang Cai, Chunli Liu, Minjie Ma, Wendong Qu, Sheng Zhong, Enkuo Zheng, Huangkai Zhu, Feng Jin et al. · 2023 · European Radiology
49. Treatment patterns and clinical outcomes of patients with resectable non–small cell lung cancer receiving neoadjuvant immunochemotherapy: A large-scale, multicenter, real-world study (NeoR-World)
    Zhenlin Yang, Shuaibo Wang, Haitang Yang, Yina Jiang, Linhai Zhu, Bin Zheng, Honghao Fu, Junliang Ma, Hounai Xie, Zhiqiang Wang et al. · 2024 · Journal of Thoracic and Cardiovascular Surgery
50. Analysis of Circulating Tumor DNA Predicts Outcomes of Short-Course Consolidation Immunotherapy in Unresectable Stage III NSCLC
    Soyeong Jun, Nikhil Atul Shukla, Greg Andrew Durm, Angela Bik‐Yu Hui, Sha Cao, Apar Kishor Ganti, Salma K. Jabbour, Christian A. Kunder, Ash A. Alizadeh, Nasser H. Hanna et al. · 2024 · Journal of Thoracic Oncology
51. Cracking the Codes behind Cancer Cells’ Immune Evasion
    Nikita Mundhara, Pritam Sadhukhan · 2024 · International Journal of Molecular Sciences
52. Neoadjuvant and Adjuvant Immune-based Approach for Renal Cell Carcinoma: Pros, Cons, and Future Directions
    Laura Marandino, Riccardo Campi, Daniele Amparore, Zayd Tippu, Laurence K. Albiges, Umberto Capitanio A, Rachel H. Giles, Silke Gillessen, Alexander Kutikov, James Larkin et al. · 2024 · European Urology Oncology
53. Gut Microbiota in Immuno-Oncology: A Practical Guide for Medical Oncologists With a Focus on Antibiotics Stewardship
    Arielle Elkrief, Bertrand Routy, Lisa Derosa, Laura A. Bolte, Jennifer Ann Wargo, Jennifer Leigh McQuade, Laurence Zitvogel · 2025 · American Society of Clinical Oncology Educational Book
54. Immune checkpoint blockade: timing is everything
    Frank A. Sinicrope, Mary Jo Turk · 2024 · Journal for ImmunoTherapy of Cancer
55. Ultrasound-triggered drug-loaded nanobubbles for enhanced T cell recruitment in cancer chemoimmunotherapy
    Deng Liu, Yi Ling, Li J. Dong, Jun Zhang, Xin Li, Xuemei Chen, Haiyun Huang, Jun Deng, Yanli Guo · 2025 · Biomaterials
56. Challenges and Future Directions in the Management of Tumor Mutational Burden-High (TMB-H) Advanced Solid Malignancies
    Jibran Ahmed, Biswajit Das, Sarah J. Shin, Alice P. Chen · 2023 · Cancers
57. Diagnosing and Managing Uveitis Associated with Immune Checkpoint Inhibitors: A Review
    Huixin Zhang, Lysa Houadj, Kevin Yang Wu, Simon D. Tran · 2024 · Diagnostics
58. Tertiary lymphoid structures: new immunotherapy biomarker
    Fangyuan Yang, Jiahe Yang, Meijuan Wu, Cheng Yeh Chen, Xiaoyuan Chu · 2024 · Frontiers in Immunology
59. Surgical Outcomes With Neoadjuvant Durvalumab Plus Chemotherapy Followed by Adjuvant Durvalumab in Resectable NSCLC
    Tetsuya Mitsudomi, John Victor Heymach, Martin Reck, Janis Marie Taube, Shugeng Gao, Yoshitsugu Horio, Jian You, Gaofeng Li, Dinh Van Luong, Somcharoen Saeteng et al. · 2025 · Journal of Thoracic Oncology
60. Adebrelimab (SHR-1316) in Combination With Chemotherapy as Perioperative Treatment in Patients With Resectable Stage II to III NSCLCs: An Open-Label, Multicenter, Phase 1b Trial
    Wanpu Yan, Wen‐Zhao Zhong, Yan‐Hui Liu, Qixun Chen, Wenqun Xing, Qin Zhang, Lunxu Liu, Di Ge, Ke‐Neng Chen, Fan Yang et al. · 2022 · Journal of Thoracic Oncology
61. Liquid Biopsy in NSCLC: An Investigation with Multiple Clinical Implications
    Elisa Bertoli, Elisa De Carlo, Debora Basile, Diego Zara, Brigida Stanzione, Mónica Schiappacassi, Alessandro Del Conte, Michele Spina, Alessandra Bearz · 2023 · International Journal of Molecular Sciences
62. Future indications and clinical management for fecal microbiota transplantation (FMT) in immuno-oncology
    Jamal, Rahima, Messaoudene, Meriem, de Figuieredo, Marina, Routy, Bertrand · 2023 · Seminars in Immunology
63. Subcutaneous versus intravenous nivolumab for renal cell carcinoma
    Albiges, L., Bourlon, M.T., Chacón, M., Cutuli, H.J., Chuken, Y.A.L., Żurawski, B., Mota, J.M., Magri, I., Burotto, M., Luz, M. et al. · 2025 · Annals of Oncology
64. The effect of organ-specific tumor microenvironments on response patterns to immunotherapy
    Jordan W. Conway, Jorja Braden, James S. Wilmott, Richard A. Scolyer, Georgina Venetia Long, Inês Pires da Silva · 2022 · Frontiers in Immunology
65. Development of new techniques and clinical applications of liquid biopsy in lung cancer management
    Kezhong Chen, Yue He, Wenxiang Wang, Xiaoqiu Yuan, David Paul Carbone, Fan Yang · 2024 · 中国科学通报：英文版
66. Tumor Heterogeneity and the Immune Response in Non-Small Cell Lung Cancer: Emerging Insights and Implications for Immunotherapy
    Michael S. Oh, Jensen W. Abascal, Austin K. Rennels, Ramin Salehi‐Rad, Steven M. Dubinett, Bin Liu · 2025 · Cancers
67. A snapshot of lung cancer: where are we now?—a narrative review
    Gogo-ogute E. Ibodeng, Ifeanyi Nnamdi Uche, Ruth Mokua, Michael Galo, Brendan E. Odigwe, Jose Nahun Galeas, Santanu Dasgupta · 2023 · Annals of Translational Medicine
68. Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC
    Kah Yee Goh, Terence You De Cheng, Su Chin Tham, Wan‐Teck Lim · 2023 · Biomedicines
69. Multi-Omics Analysis Reveals Intratumor Microbes as Immunomodulators in Colorectal Cancer
    Zhi Liu, Xuemei Zhang, Haoding Zhang, Hong Zhang, Zhongyuan Yi, Qingqing Zhang, Qisha Liu, Xingyin Liu · 2023 · Microbiology Spectrum
70. Early-Stage Lung Cancer: Using Circulating Tumor DNA to Get Personal
    Christine M. Bestvina, Marina Chiara Garassino, Joel W. Neal, Heather A. Wakelee, Maximilian Diehn, Everett E. Vokes · 2023 · Journal of Clinical Oncology
71. Final analysis of a phase II trial of neoadjuvant chemoimmunotherapy for locoregionally advanced head and neck squamous cell carcinoma
    Xueyan Zhao, Yan Feng Zhou, Gang Peng, Lu Wen, Xiaohua Hong, Yuan Hu, Bian Wu, Xixi Liu, Zhanjie Zhang, Guixiang Xiao et al. · 2024 · Oral Oncology
72. Neoadjuvant and Adjuvant Systemic Therapy for Early-Stage Non-small-Cell Lung Cancer
    James Isaacs, Thomas E. Stinchcombe · 2022 · Drugs
73. Targeting Cellular Components of the Tumor Microenvironment in Solid Malignancies
    Carmen Belli, Gabriele Antonarelli, Matteo Repetto, Luca Boscolo Bielo, Edoardo Crimini, Giuseppe Curigliano · 2022 · Cancers
74. Respiratory and Cardiometabolic Comorbidities and Stages I to III NSCLC Survival: A Pooled Analysis From the International Lung Cancer Consortium
    Miguel García-Pardo, Amy Chang, Sabine Schmid, Mei Dong, M. Catherine Brown, David C. Christiani, Hilary Aurora Tindel, Paul Brennan, Chu Chen, Jie Zhang et al. · 2022 · Journal of Thoracic Oncology
75. Synergism Antiproliferative Effects of Apigenin and Naringenin in NSCLC Cells
    Xiongxiong Liu, Ting Zhao, Zheng Shi, Cuilan Hu, Qiang Li, Chao Sun · 2023 · Molecules
76. Personalized Cancer Monitoring Assay for the Detection of ctDNA in Patients with Solid Tumors
    Jianhua Zhao, Jacquelyn Reuther, Kaylee Scozzaro, Megan Hawley, Emily Metzger, Matthew Emery, Ingrid Chen, Michelle Barbosa, Laura Johnson, Alijah O’Connor et al. · 2023 · Molecular Diagnosis & Therapy
77. Neoadjuvant therapy in non-small cell lung cancer: basis, promise, and challenges
    Sukumar Kalvapudi, Yeshwanth Vedire, Sai Yendamuri, Joseph J. Barbi · 2023 · Frontiers in Oncology
78. Neoadjuvant nivolumab plus chemotherapy in resectable non‐small‐cell lung cancer in Japanese patients from CheckMate 816
    Tetsuya Mitsudomi, Hiroyuki Ito, Morihito Okada, Shunichi Sugawara, Yutaka Shio, Keisuke Tomii, Jiro Okami, Noriaki Sakakura, Kaoru Kubota, Kazuya Takamochi et al. · 2023 · Cancer Science
79. The landscape of immune checkpoint inhibitor clinical trials in glioblastoma: A systematic review
    Ethan Schonfeld, John Hyunkuk Choi, Andrew Tran, Lily H. Kim, Michael K. Lim · 2024 · Neuro-Oncology Advances
80. Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors
    Martina Catalano, Sonia Shabani, Jacopo Venturini, Carlotta Ottanelli, Luca Voltolini, Giandomenico Roviello · 2022 · Cancers
81. ASTRO Radiation Therapy Summary of the ASCO Guideline on Management of Stage III Non-Small Cell Lung Cancer
    Charles B. Simone, Jeffrey D. Bradley, Aileen B. Chen, Megan Eileen Daly, Alexander V. Louie, Clifford G. Robinson, Gregory M.M. Videtic, George Rodrigues · 2023 · Practical Radiation Oncology
82. Liquid Biopsy in Early-Stage Lung Cancer: Current and Future Clinical Applications
    Olivia Vandekerckhove, Kristof Cuppens, Karin Pat, Bert Du Pont, Guy Froyen, Brigitte Maes · 2023 · Cancers
83. The predictive role of hematologic markers in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy: a retrospective cohort study
    Wenliang Liu, Siying Ren, Lulu Yang, Ying Xiao, Chao Zeng, Chen Chen, Fang Wu, Yan Wei Hu · 2023 · International Journal of Surgery
84. Impact of Neoadjuvant Immune Checkpoint Inhibitors on Surgery and Perioperative Complications in Patients With Non–small-cell Lung Cancer: A Systematic Review
    Kazuki Takada, Shinkichi Takamori, Leonardo Brunetti, Pierfilippo Crucitti, Alessio Cortellini · 2023 · Clinical Lung Cancer
85. The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapy
    Francis Proulx-Rocray, Bertrand Routy, Rami Mohamad Nassabein, Wiam Belkaïd, Danh Tran‐Thanh, Julie Malo, Marion Tonneau, Omar El Ouarzadi, Marie Florescu, Mustapha Ali Tehfe et al. · 2023 · Cancer Treatment and Research Communications
86. Pan-Immune-Inflammatory Value in Patients with Non-Small-Cell Lung Cancer Undergoing Neoadjuvant Immunochemotherapy
    Wen-Yu Zhai, Fangfang Duan, Yaobin Lin, Yongbin Lin, Ze-Rui Zhao, Junye Wang, Bing-Yu Rao, Lie Zheng, Hao Long · 2023 · Journal of Inflammation Research
87. Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids
    Kanve Nagaraj Suvilesh, Yariswamy Manjunath, Yulia I. Nussbaum, Mohamed Gadelkarim, Murugesan Raju, Akhil Srivastava, Guangfu Li, Wesley C. Warren, Chi‐Ren Shyu, Feng Gao et al. · 2024 · Clinical Cancer Research
88. Innate Immune Activation with Multifunctional Nanoparticles for Cancer Immunotherapy
    Xiaomin Jiang, Wenbin Lin · 2025 · Angewandte Chemie International Edition
89. Overcoming Immunosuppression and Pro-Tumor Inflammation in Lung Cancer with Combined IL-1β and PD-1 Inhibition
    Jay M. Lee, Masahiro Tsuboi, Edward S. Kim, Tony S.K. Mok, Pilar Garrido · 2022 · Future Oncology
90. Transcriptional upregulation of CXCL13 is correlated with a favorable response to immune checkpoint inhibitors in lung adenocarcinoma
    Sehhoon Park, Hongui Cha, Hong Sook Kim, Boram Lee, Soyeon Kim, Tae Min Kim, Hyun Ae Jung, Jong‐Mu Sun, Jin Seok Ahn, Myung‐Ju Ahn et al. · 2022 · Cancer Medicine
91. p53 mutation and deletion contribute to tumor immune evasion
    Si‐Yang Maggie Liu, Tianyao Liu, Jiaxuan Jiang, Hongqian Guo, Rong Li Yang · 2023 · Frontiers in Genetics
92. Neoadjuvant Immunotherapy: A Promising New Standard of Care
    Emma Boydell, José Luís Sandoval, Olivier Alain Michielin, Michel Obéid, Alfredo Addeo, Alex Friedlaender · 2023 · International Journal of Molecular Sciences
93. A Review of Biomarkers and Their Clinical Impact in Resected Early-Stage Non-Small-Cell Lung Cancer
    Weibo Cao, Quanying Tang, Jingtong Zeng, Xin Jin, Lingling Zu, Song Xu · 2023 · Cancers
94. Combined inflammatory parameters and tertiary lymphoid structure predict prognosis in patients with resectable non-small cell lung cancer treated with neoadjuvant chemoimmunotherapy
    Fuhao Xu, He Zhu, Yinjun Dong, Li Li, Ning Liu, Shuanghu Yuan · 2023 · Frontiers in Immunology
95. Neoadjuvant Chemoimmunotherapy Complicates Subsequent Surgical Resection and Adjuvant Immunotherapy Is Preferable From the Surgical Standpoint
    Paula Ugalde Figueroa, Valérie Lacroix, Paul E. Van Schil · 2024 · Journal of Thoracic Oncology
96. The Gut Microbiome from a Biomarker to a Novel Therapeutic Strategy for Immunotherapy Response in Patients with Lung Cancer
    Sreya Duttagupta, Taiki Hakozaki, Bertrand Routy, Meriem Messaoudene · 2023 · Current Oncology
97. The discovery and evaluation of [18F]BMS-986229, a novel macrocyclic peptide PET radioligand for the measurement of PD-L1 expression and in-vivo PD-L1 target engagement
    David J. Donnelly, Joon‐Young Kim, Tritin Tran, Paul M. Scola, Daniel J. Tenney, Adrienne Pena, Thomas V. Petrone, Yunhui Zhang, Kenneth M. Boy, Michael A. Poss et al. · 2023 · European Journal of Nuclear Medicine and Molecular Imaging
98. The safety and efficacy of neoadjuvant immunochemotherapy following laparoscopic gastrectomy for gastric cancer: a multicentre real-world clinical study
    Yuqin Sun, Qing Zhong, Chen-Bin Lv, Jiyun Zhu, Guang‐Tan Lin, Zhi-Quan Zhang, Dong Wu, Cai-Ming Weng, Qiu‐Xian Chen, Mingqiao Lian et al. · 2024 · International Journal of Surgery
99. The miRNA and PD-1/PD-L1 signaling axis: an arsenal of immunotherapeutic targets against lung cancer
    Ritu Yadav, Rinku Khatkar, Kenneth Chun-Yong Yap, Chloe Kang, Juncheng Lyu, RAHUL KUMAR SINGH, Surojit Mandal, Adrija Mohanta, Hiu Yan Lam, Elena Okina et al. · 2024 · Cell Death Discovery
100. Reprogramming cancer immunity with next-generation combination therapies
     Nikolaos C. Kyriakidis, Carolina E. Echeverría, Jhommara Bautista, Sebastián Rivera-Orellana, María José Ramos-Medina, Camila Salazar-Santoliva, Juan S. Izquierdo‐Condoy, Esteban Ortiz‐Prado, Santiago Xavier Guerrero, Andrés López‐Cortés · 2025 · Frontiers in Cell and Developmental Biology